Medical device company Remedi lists on the KOSDAQ market January 13 at a public offering price of ₩20,700 per share. Pharmaceutical ingredient manufacturer HLGenomics conducts public subscription January 13-14 at ₩21,500 per share with listing scheduled January 24. Remedi's institutional demand forecasting attracted 2,246 participants with a 1,146:1 ratio, and general subscription January 1-2 reached 1,701:1 with 512 million shares applied for 300,000 allocated shares. The week features multiple corporate actions including rights offerings by Hansolteknics and Hyungji I&C, reflecting active IPO market conditions in Korea.
Remedi Lists on KOSDAQ January 13 at ₩20,700 Per Share
Remedi's public offering price is ₩20,700, the upper end of the希望 range. First-day trading prices can move between ₩12,420 and ₩82,800, representing 60% to 400% of the offering price. The company develops portable X-ray imaging devices and non-destructive testing solutions for medical and industrial use using proprietary technology. Remedi applies miniaturized X-ray technology to industrial inspection and telemedicine, and expands business scope into aerospace and AI-based digital imaging solutions.
HLGenomics Conducts Public Subscription January 13-14
HLGenomics accepts general subscription January 13-14, with refund date January 16 and KOSDAQ listing scheduled January 24. KB Securities serves as lead underwriter and IBK Investment & Securities as co-underwriter. The final offering price is ₩21,500, the upper end of the ₩18,500-₩21,500 range, after 94.8% of institutional demand forecasting volume submitted prices at or above the upper range. Total offering volume is 2,565,000 shares, comprising 855,000 existing shares from Hallim Pharmaceutical and 1,710,000 new shares. Existing share sales represent 33.3% and new share issuance represents 66.7%. Institutional investors and general investors receive 75% and 25% of total volume respectively.
HLGenomics supplies raw materials to finished pharmaceutical manufacturers, focusing on high-difficulty, high-value-added active pharmaceutical ingredients. Hallim Pharmaceutical owns 100% equity and HLGenomics is the first Hallim affiliate to enter the stock market. Funds from new share issuance will be invested in second factory expansion to increase production capacity, improve supply stability of existing active pharmaceutical ingredients, and establish new business foundations including vaccine microneedle business. DB Securities analyst Lee Myung-sun stated that customer diversification and overseas sales growth potential after second factory expansion are evaluated as strengths, but noted that stock price upside will be limited if overseas sales do not increase meaningfully and customer diversification is delayed, preventing rapid second factory utilization rate increases.
Hansolteknics and Hyungji I&C Schedule Rights Offerings
Hansolteknics conducts existing shareholder subscription January 13-14, followed by forfeited share subscription January 16. Hyungji I&C conducts forfeited share subscription January 14-15. CurioSys' bonus share issuance and Futurechem's rights offering new share allocation base date is January 16.
FAQ
What is Remedi's KOSDAQ listing date and offering price?
Remedi lists on the KOSDAQ market January 13 at a public offering price of ₩20,700 per share, the upper end of the希望 range. First-day trading prices can move between ₩12,420 and ₩82,800.
When does HLGenomics conduct public subscription and what is the offering price?
HLGenomics conducts public subscription January 13-14 at a final offering price of ₩21,500 per share, with KOSDAQ listing scheduled January 24. Total offering volume is 2,565,000 shares, with institutional investors receiving 75% and general investors receiving 25%.
What rights offerings are scheduled this week?
Hansolteknics conducts existing shareholder subscription January 13-14 and forfeited share subscription January 16. Hyungji I&C conducts forfeited share subscription January 14-15. CurioSys' bonus share issuance and Futurechem's rights offering new share allocation base date is January 16.
